A Four-Year, Open-Label, Multi-Center, Randomized, Two-Arm Study of Genotropin® in Patients with Idiopathic Short Stature: Comparison of an Individualized, Target-Driven Treatment Regimen to Standard Dosing of Genotropin® - Analysis of Two-Year Data

By  

Hormone Research in Paediatrics, Vol. 80, Iss. 4, 2013-09 ,pp. : 242-251

Karger

Access to resources Recommend Favorite

Optimization of Growth Hormone Dosing in Children Born Small for Gestational Age: An Open-Label, Randomized Study of Children during the Fourth Year of Therapy

By  

Hormone Research in Paediatrics, Vol. 77, Iss. 3, 2012-04 ,pp. : 156-163

Karger

Access to resources Recommend Favorite

Bone Age Progression during the First Year of Growth Hormone Therapy in Pre-Pubertal Children with Idiopathic Growth Hormone Deficiency, Turner Syndrome or Idiopathic Short Stature, and in Short Children Born Small for Gestational Age: Analysis of Data from KIGS (Pfizer International Growth Database)

By  

Hormone Research in Paediatrics, Vol. 63, Iss. 1, 2005-01 ,pp. : 40-47

Karger

Access to resources Recommend Favorite

Optimizing Growth Hormone Dosing in Children with Idiopathic Short Stature

By  

Hormone Research in Paediatrics, Vol. 71, Iss. 1, 2009-01 ,pp. : 70-74

Karger

Access to resources Recommend Favorite

Recombinant Human Growth Hormone Plus Recombinant Human Insulin-Like Growth Factor-1 Coadministration Therapy in Short Children with Low Insulin-Like Growth Factor-1 and Growth Hormone Sufficiency: Results from a Randomized, Multicenter, Open-Label, Parallel-Group, Active Treatment-Controlled Trial

By  

Hormone Research in Paediatrics, Vol. 83, Iss. 4, 2015-03 ,pp. : 268-279

Karger

Access to resources Recommend Favorite